{
    "root": "30955535-047e-363e-e063-6294a90a3d02",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Omeprazole",
    "value": "20250306",
    "ingredients": [
        {
            "name": "GLYCERYL MONOSTEARATE",
            "code": "230OU9XXE4",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11250"
        },
        {
            "name": "HYPROMELLOSES",
            "code": "3NXW29V3WO",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "MEGLUMINE",
            "code": "6HG8UB2MUY",
            "drugbank_id": "https://go.drugbank.com/drugs/DB09415"
        },
        {
            "name": "METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A",
            "code": "NX76LV5T8J",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_25219"
        },
        {
            "name": "POLOXAMER 407",
            "code": "TUF2IVW3M2",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32026"
        },
        {
            "name": "RAW SUGAR",
            "code": "8M707QY5GH"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32178"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "TRIETHYL CITRATE",
            "code": "8Z96QXD6UM",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_168426"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50821"
        },
        {
            "name": "D&C RED NO. 28",
            "code": "767IP0Y5NH"
        },
        {
            "name": "FD&C BLUE NO. 1",
            "code": "H3R47K3TBD"
        },
        {
            "name": "FD&C RED NO. 40",
            "code": "WZB9127XOA"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "GELATIN",
            "code": "2G86QN327L",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_5291"
        },
        {
            "name": "POTASSIUM HYDROXIDE",
            "code": "WZH3C48M4T",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32035"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "OMEPRAZOLE",
            "code": "KG60484QX9",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_7772"
        }
    ],
    "indications": {
        "text": "omeprazole proton pump inhibitor ( ppi ) indicated : \u2022 treatment active duodenal ulcer adults ( 1.1 ) \u2022 eradication helicobacter pylori reduce risk duodenal ulcer recurrence adults ( 1.2 ) \u2022 treatment active benign gastric ulcer adults ( 1.3 ) \u2022 treatment symptomatic gastroesophageal reflux disease ( gerd ) patients 2 years age older ( 1.4 ) \u2022 maintenance healing ee due acid-mediated gerd patients 2 years age older ( 1.6 ) \u2022 pathologic hypersecretory conditions adults ( 1.7 )",
        "doid_entities": [
            {
                "text": "duodenal ulcer (DOID:1724)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1724"
            },
            {
                "text": "gastric ulcer (DOID:10808)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_10808"
            },
            {
                "text": "gastroesophageal reflux (DOID:8534)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_8534"
            },
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "indication recommended adult ( 2.1 ) pediatric ( 2.2 ) treatment active duodenal ulcer 20 mg daily 4 weeks ; patients may require additional 4 weeks ( 2.1 ) h. pylori eradication reduce risk duodenal ulcer recurrence triple therapy : omeprazole delayed-release capsules amoxicillin clarithromycin 20 mg 1000 mg 500 mg twice daily 10 days ( 2.1 ) * dual therapy : omeprazole delayed-release capsules clarithromycin 40 mg daily 14 days * * 500 mg three times daily 14 days ( 2.1 ) active benign gastric ulcer 40 mg daily 4 8 weeks ( 2.1 ) symptomatic gerd 20 mg daily 4 weeks ( 2.1 ) full prescribing information weight based dosing pediatric patients 2 years age older ( 2.2 ) ee due acid-mediated gerd 20 mg daily 4 8 weeks ( 2.1 ) * * * maintenance healing ee due acid-mediated gerd 20 mg daily ( 2.1 ) * * * * full prescribing information weight based dosing pediatric patients 2 years age older ( 2.2 ) pathological hypersecretory conditions starting dose 60 mg daily ( varies individual patient , full prescribing information ) long clinically indicated ( 2.1 ) * ulcer present , continue omeprazole delayed-release capsules 20 mg daily additional 18 days . * * ulcer present , continue omeprazole delayed-release capsules 20 mg daily additional 14 days . * * * additional 4 weeks treatment may given response ; recurrence additional 4 8 week courses may considered . * * * * studied 12 months . reduce 10 mg daily patients hepatic impairment ( child-pugh class , b , c ) asian patients ( 8.6 , 8.7 )",
        "doid_entities": [
            {
                "text": "duodenal ulcer (DOID:1724)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1724"
            },
            {
                "text": "gastric ulcer (DOID:10808)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_10808"
            },
            {
                "text": "gerd (DOID:8534)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_8534"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "omeprazole delayed-release capsules usp , 20 mg off-white pale yellow , spherical , enteric coated pellets filled size ' 2 ' hard gelatin capsule shells opaque purple colored cap opaque grey colored body , imprinted 'omeprazole ' 20 mg cap 'r644 ' body black ink supplied bottles 30 capsules ndc : 80425-0504-01 bottles 60 capsules ndc : 80425-0504-02 bottles 90 capsules ndc : 80425-0504-03 bottles 120 capsules ndc : 80425-0504-04 storage store omeprazole delayed-release capsules tight container protected light moisture . store 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) [ usp controlled room temperature ] .",
    "adverseReactions": "\u2022 omeprazole delayed-release capsules contraindicated patients known hypersensitivity including anaphylaxis formulation substituted benzimidazole . hypersensitivity may include anaphylaxis , anaphylactic shock , angioedema , bronchospasm , acute tubulointerstitial nephritis , urticaria [ ( 5.2 ) , ( 6 ) ] . \u2022 proton pump inhibitors ( ppis ) , including omeprazole , contraindicated patients receiving rilpivirine-containing products [ ( 7 ) ] . \u2022 information antibacterial agents ( clarithromycin amoxicillin ) indicated combination omeprazole , refer section package inserts .",
    "indications_original": "Omeprazole is a proton pump inhibitor (PPI) indicated for the: \u2022 Treatment of active duodenal ulcer in adults (1.1) \u2022 Eradication of Helicobacter pylori to reduce the risk of duodenal ulcer recurrence in adults (1.2) \u2022 Treatment of active benign gastric ulcer in adults (1.3) \u2022 Treatment of symptomatic gastroesophageal reflux disease (GERD) in patients 2 years of age and older (1.4) \u2022 Maintenance of healing of EE due to acid-mediated GERD in patients 2 years of age and older (1.6) \u2022 Pathologic hypersecretory conditions in adults (1.7)",
    "contraindications_original": "Indication Recommended Adult (2.1) and Pediatric Dosage (2.2) Treatment of Active Duodenal Ulcer 20 mg once daily for 4 weeks; some patients may require an additional 4 weeks (2.1) H. pylori\u00a0Eradication to Reduce the Risk of Duodenal Ulcer Recurrence Triple Therapy: Omeprazole delayed-release capsules Amoxicillin Clarithromycin 20 mg 1000 mg 500 mg Each drug twice daily for 10 days (2.1) * Dual Therapy: Omeprazole delayed-release capsules Clarithromycin 40 mg once daily for 14 days** 500 mg three times daily for 14 days (2.1) Active Benign Gastric Ulcer 40 mg once daily for 4 to 8 weeks (2.1) Symptomatic GERD 20 mg once daily for up to 4 weeks (2.1) See full prescribing information for weight based dosing in pediatric patients 2 years of age and older (2.2) EE due to Acid-Mediated GERD 20 mg once daily for 4 to 8 weeks (2.1) *** Maintenance of Healing of EE due to Acid-Mediated GERD 20 mg once daily (2.1) **** See full prescribing information for weight based dosing in pediatric patients 2 years of age and older (2.2) Pathological Hypersecretory Conditions Starting dose is 60 mg once daily (varies with individual patient, see full prescribing information) as long as clinically indicated (2.1) * if ulcer present, continue omeprazole delayed-release capsules 20 mg once daily for an additional 18 days. ** if ulcer present, continue omeprazole delayed-release capsules 20 mg once daily for an additional 14 days. *** an additional 4 weeks of treatment may be given if no response; if recurrence additional 4 to 8 week courses may be considered. **** studied for 12 months. Reduce the dosage to 10 mg once daily for patients with hepatic impairment (Child-Pugh Class A, B, or C) and Asian patients ( 8.6 , 8.7 )",
    "warningsAndPrecautions_original": "Omeprazole delayed-release capsules USP, 20 mg are off-white to pale yellow, spherical, enteric coated pellets filled in size '2' hard gelatin capsule shells with opaque purple colored cap and opaque grey colored body,imprinted 'OMEPRAZOLE' 20 mg on cap and 'R644' on body with black ink and are supplied in\n                  Bottles of 30 Capsules NDC: 80425-0504-01\n                  Bottles of 60 Capsules NDC: 80425-0504-02\n                  Bottles of 90 Capsules NDC: 80425-0504-03\n                  Bottles of 120 Capsules NDC: 80425-0504-04\n                  \n                  \n                     Storage\n                  \n                  Store omeprazole delayed-release capsules in a tight container protected from light and moisture. Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F) [See USP Controlled Room Temperature].",
    "adverseReactions_original": "\u2022 Omeprazole delayed-release capsules are contraindicated in patients with known hypersensitivity reactions including anaphylaxis to the formulation or any substituted benzimidazole. Hypersensitivity reactions may include anaphylaxis, anaphylactic shock, angioedema, bronchospasm, acute tubulointerstitial nephritis, and urticaria [see Warnings and Precautions (\n \n  5.2), Adverse Reactions\n \n  (6)].\n\n \n                  \u2022 Proton pump inhibitors (PPIs), including omeprazole, are contraindicated in patients receiving rilpivirine-containing products [see Drug Interactions\n \n  \n                     (7)].\n\n \n                  \u2022 For information about contraindications of antibacterial agents (clarithromycin and amoxicillin) indicated in combination with omeprazole, refer to the CONTRAINDICATIONS section of their package inserts.",
    "drug": [
        {
            "name": "Omeprazole",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_7772"
        }
    ]
}